Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | Chief Financial Officer | January 25, 2019 | January 29, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytomX Therapeutics, Inc.
Report date January 25, 2019 · Filed January 29, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.85 · Expires 2029-01-24 | Direct | 90,000 |
Reported balance
After 2019-01-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-25 · Grant · Acquired 90,000 · Balance 90,000 F1: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2019 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2019 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 25, 2019 Filed Jan 29, 2019 23:57 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $16.85 | $0.00 |
DisclosureSEC source: 0001567619-19-001863 · doc1.xml · derivative · entry 1 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2029-01-24 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2019 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 20:23 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001567619-18-008005 · doc1.xml · derivative · entry 3 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,220 Underlying: Common Stock · 3,000 shares Expires 2024-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 20:23 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 3,000 | $15.00 | $45,000.00 |
DisclosureSEC source: 0001567619-18-008005 · doc1.xml · nonDerivative · entry 2 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,928 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 20:23 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 3,000 | $1.45 | $4,346.70 |
DisclosureSEC source: 0001567619-18-008005 · doc1.xml · nonDerivative · entry 1 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 21:15 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001567619-18-005082 · doc1.xml · derivative · entry 3 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,220 Underlying: Common Stock · 3,000 shares Expires 2024-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 21:15 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 3,000 | $15.00 | $45,000.00 |
DisclosureSEC source: 0001567619-18-005082 · doc1.xml · nonDerivative · entry 2 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,928 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 21:15 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 3,000 | $1.45 | $4,346.70 |
DisclosureSEC source: 0001567619-18-005082 · doc1.xml · nonDerivative · entry 1 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 19:18 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001567619-18-003477 · doc1.xml · derivative · entry 3 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,220 Underlying: Common Stock · 3,000 shares Expires 2024-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 19:18 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 3,000 | $18.46 | $55,380.00 |
DisclosureSEC source: 0001567619-18-003477 · doc1.xml · nonDerivative · entry 2 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,928 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 19:18 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 3,000 | $1.45 | $4,346.70 |
DisclosureSEC source: 0001567619-18-003477 · doc1.xml · nonDerivative · entry 1 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 23:18 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001567619-18-002232 · doc1.xml · derivative · entry 3 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,220 Underlying: Common Stock · 3,000 shares Expires 2024-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 23:18 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 3,000 | $22.39 | $67,170.00 |
DisclosureSEC source: 0001567619-18-002232 · doc1.xml · nonDerivative · entry 2 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,928 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 23:18 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 3,000 | $1.45 | $4,346.70 |
DisclosureSEC source: 0001567619-18-002232 · doc1.xml · nonDerivative · entry 1 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 00:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 290 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001140361-18-035277 · doc1.xml · derivative · entry 5 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,220 Underlying: Common Stock · 290 shares Expires 2024-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 00:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,710 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001140361-18-035277 · doc1.xml · derivative · entry 4 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,710 shares Expires 2023-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 00:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 3,000 | $26.05 | $78,150.00 |
DisclosureSEC source: 0001140361-18-035277 · doc1.xml · nonDerivative · entry 3 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,928 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 00:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 290 | $1.45 | $420.18 |
DisclosureSEC source: 0001140361-18-035277 · doc1.xml · nonDerivative · entry 2 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 00:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 2,710 | $1.26 | $3,414.33 |
DisclosureSEC source: 0001140361-18-035277 · doc1.xml · nonDerivative · entry 1 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 22:51 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001140361-18-031328 · doc1.xml · derivative · entry 3 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,710 Underlying: Common Stock · 3,000 shares Expires 2023-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 22:51 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 3,000 | $22.56 | $67,680.00 |
DisclosureSEC source: 0001140361-18-031328 · doc1.xml · nonDerivative · entry 2 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,928 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 22:51 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 3,000 | $1.26 | $3,779.70 |
DisclosureSEC source: 0001140361-18-031328 · doc1.xml · nonDerivative · entry 1 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 23:46 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001140361-18-027475 · doc1.xml · derivative · entry 4 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,710 Underlying: Common Stock · 3,000 shares Expires 2023-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 23:46 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 3,000 | $25.93 | $77,793.00 |
DisclosureSEC source: 0001140361-18-027475 · doc1.xml · nonDerivative · entry 3 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,928 F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades in prices ranging from $25.75 to $26.25, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F1 · balance_after: The shares were acquired under the issuer's Employee Stock Purchase Plan on May 31, 2018. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 23:46 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 3,000 | $1.26 | $3,779.70 |
DisclosureSEC source: 0001140361-18-027475 · doc1.xml · nonDerivative · entry 2 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| May 31, 2018 Filed Jun 5, 2018 23:46 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 1,187 | $17.90 | $21,248.49 |
DisclosureSEC source: 0001140361-18-027475 · doc1.xml · nonDerivative · entry 1 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,928 F1 · shares: The shares were acquired under the issuer's Employee Stock Purchase Plan on May 31, 2018. Read SEC document |
| May 01, 2018 Filed May 2, 2018 22:26 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001140361-18-021345 · doc1.xml · derivative · entry 3 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,710 Underlying: Common Stock · 3,000 shares Expires 2023-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| May 01, 2018 Filed May 2, 2018 22:26 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 3,000 | $26.52 | $79,562.10 |
DisclosureSEC source: 0001140361-18-021345 · doc1.xml · nonDerivative · entry 2 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,741 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $26.22 to $26.75, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 01, 2018 Filed May 2, 2018 22:26 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 3,000 | $1.26 | $3,779.70 |
DisclosureSEC source: 0001140361-18-021345 · doc1.xml · nonDerivative · entry 1 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 18:27 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001140361-18-016993 · doc1.xml · derivative · entry 3 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,710 Underlying: Common Stock · 3,000 shares Expires 2023-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 18:27 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 3,000 | $28.12 | $84,360.00 |
DisclosureSEC source: 0001140361-18-016993 · doc1.xml · nonDerivative · entry 2 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,741 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 18:27 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 3,000 | $1.26 | $3,779.70 |
DisclosureSEC source: 0001140361-18-016993 · doc1.xml · nonDerivative · entry 1 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2018 Filed Mar 5, 2018 21:56 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,485 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001140361-18-012009 · doc1.xml · derivative · entry 10 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 14,485 shares Expires 2021-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| March 02, 2018 Filed Mar 5, 2018 21:56 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,515 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001140361-18-012009 · doc1.xml · derivative · entry 9 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,710 Underlying: Common Stock · 5,515 shares Expires 2023-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| March 02, 2018 Filed Mar 5, 2018 21:56 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 1,944 | $31.02 | $60,293.16 |
DisclosureSEC source: 0001140361-18-012009 · doc1.xml · nonDerivative · entry 7 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,741 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.09, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 02, 2018 Filed Mar 5, 2018 21:56 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 12,541 | $30.41 | $381,384.35 |
DisclosureSEC source: 0001140361-18-012009 · doc1.xml · nonDerivative · entry 6 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,685 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.99, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 02, 2018 Filed Mar 5, 2018 21:56 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 14,485 | $1.13 | $16,424.54 |
DisclosureSEC source: 0001140361-18-012009 · doc1.xml · nonDerivative · entry 5 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,226 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2018 Filed Mar 5, 2018 21:56 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 5,515 | $30.06 | $165,775.39 |
DisclosureSEC source: 0001140361-18-012009 · doc1.xml · nonDerivative · entry 4 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,741 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.38, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 02, 2018 Filed Mar 5, 2018 21:56 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 5,515 | $1.26 | $6,948.35 |
DisclosureSEC source: 0001140361-18-012009 · doc1.xml · nonDerivative · entry 3 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:56 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001140361-18-012009 · doc1.xml · derivative · entry 8 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,225 Underlying: Common Stock · 13,000 shares Expires 2023-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:56 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 13,000 | $29.40 | $382,241.60 |
DisclosureSEC source: 0001140361-18-012009 · doc1.xml · nonDerivative · entry 2 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,741 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.81, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:56 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 13,000 | $1.26 | $16,378.70 |
DisclosureSEC source: 0001140361-18-012009 · doc1.xml · nonDerivative · entry 1 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2018 Filed Feb 3, 2018 00:28 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 2,548 | $26.69 | $68,009.94 |
DisclosureSEC source: 0001140361-18-004851 · doc1.xml · nonDerivative · entry 1 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,741 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $26.39 to $27.19, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 19:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $25.82 | $0.00 |
DisclosureSEC source: 0001140361-18-003376 · doc1.xml · derivative · entry 1 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-01-23 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2018 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 20:23 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 2,500 | $21.11 | $52,775.00 |
DisclosureSEC source: 0001140361-18-000410 · doc1.xml · nonDerivative · entry 1 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,289 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 17:56 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 2,500 | $20.58 | $51,450.00 |
DisclosureSEC source: 0001140361-17-045018 · doc1.xml · nonDerivative · entry 2 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,789 F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| November 30, 2017 Filed Dec 5, 2017 17:56 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 163 | $12.15 | $1,979.88 |
DisclosureSEC source: 0001140361-17-045018 · doc1.xml · nonDerivative · entry 1 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,289 F1 · kind: 163 shares were acquired pursuant to the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 20:33 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 2,500 | $20.00 | $50,000.00 |
DisclosureSEC source: 0001140361-17-040975 · doc1.xml · nonDerivative · entry 1 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,126 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 16:38 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 2,500 | $18.10 | $45,250.00 |
DisclosureSEC source: 0001140361-17-037554 · doc1.xml · nonDerivative · entry 1 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,626 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 22:18 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 2,500 | $17.17 | $42,925.00 |
DisclosureSEC source: 0001140361-17-034349 · doc1.xml · nonDerivative · entry 1 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,126 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 16:51 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 2,500 | $15.00 | $37,500.00 |
DisclosureSEC source: 0001140361-17-031316 · doc1.xml · nonDerivative · entry 1 RAY DEBANJAN · CIK 0001706863 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,626 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.